ArticleSurgical neurology international2025
Dexamethasone-associated regression of glioblastoma.
Article in Surgical neurology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systems biology-driven drug repurposing in glioblastomaResearch in pharmaceutical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dexamethasone-induced regression of an intracranial space-occupying lesion is commonly characteristic of primary central nervous system lymphoma (PCNSL). However, dexamethasone does not have an established chemotherapeutic role in glioblastoma multiforme (GBM). This is a report on dexamethasone-induced regression in GBM with the aim of exploring the mechanisms behind the phenomenon. Case Description: We present the case of a 63-year-old male presenting with status epilepticus. Initial imaging showed a high-grade glioma with significant vasogenic edema. Following 23 days of dexamethasone therapy, magnetic resonance imaging demonstrated notable tumor regression, raising differential diagnoses, including lymphoma or a nonneoplastic inflammatory process. After discontinuation of dexamethasone, the tumor rapidly regrew. A biopsy confirmed the diagnosis of high-grade glioma. Immunohistochemistry revealed the following: glial fibrillary acidic protein positive, isocitrate dehydrogenase-1 (IDH-1) R132H negative, ATP-dependent helicase ATRX (ATRX) positive, p53 with 30% nuclear labeling index, and Ki-67 with maximal labeling index of 25%. The patient underwent an image-guided awake craniotomy for tumor resection. Conclusion: This case demonstrates substantial dexamethasone-induced GBM regression in our patient, serving as a diagnostic confounder with PCNSL. The decision to wean steroids with the aim of increasing diagnostic yield for PCNSL resulted in a missed opportunity for early surgery for GBM, with the development of neurological symptoms, higher surgical risk and possibly shorter survival. Healthcare professionals caring for patients with suspected GBM must be aware of this potential pitfall in rare cases, planning for timely surgical intervention to optimize the outcome for such patients. This case introduces the second case of a GBM behaving in such a manner, along with molecular characterization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.